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Background: The objective of this randomized, double-blind, placebo-controlled study was to evaluate the
efficacy of sustained-release methylphenidate (MPH-SR) in treatment of methamphetamine dependence.
Methods: Fifty-six individuals who met DSM-IV-TR criteria for methamphetamine dependence participated in this
10-week trial. The participants were randomly allocated into two groups and received 18 to 54 mg/day sustained-
released methylphenidate or placebo for 10 weeks. Craving was evaluated by a visual analogue craving scale
every week. Urinary screening test for methamphetamine was carried out each week. The Beck Depression
Inventory-II (BDI-II) was used to monitor participant depressive symptoms at baseline and bi-weekly during the
treatment period.
Results: At the end of the trial, the MPH-SR group was less methamphetamine positive compared to the placebo
group and the difference was significant (p = 0.03). By the end of the study, MPH-SR group showed significantly
less craving scores compared to the placebo group [MD (95% CI) = -10.28(0.88-19.18), t(54) = 2.19, p = 0.03]. There
was greater improvement in the depressive symptoms scores in the intervention group compared to the placebo
group [MD (95% CI) =2.03(0.31-3.75), t (54) =2.37, p = 0.02].
Conclusion: Sustained-released methylphenidate was safe and well tolerated among active methamphetamine
users and significantly reduced methamphetamine use, craving and depressive symptoms.
Trial registration: IRCT201202281556N38
Keywords: Clinical trial, Dependence, Methamphetamine, MethylphenidateBackground
Methamphetamine is a psychostimulant that is highly
addictive and affects monoamine neurotransmitter sys-
tems [1]. Methamphetamine and related stimulants are
the second most frequently used illicit drugs worldwide,
second only to cannabis. It is estimated that more than
35 million people around the world use this class of sub-
stance [2-4]. Methamphetamine dependence is associ-
ated with a number of psychiatric disorders including
depression and psychosis [5-7]. Furthermore, metham-
phetamine use is accompanied with various medical* Correspondence: s.akhond@neda.net
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unless otherwise stated.consequences such as myocardial infarction, renal fail-
ure, cerebral hemorrhage, muscle damage, nasal and
sinus damage and sudden death [8-12]. Methampheta-
mine abuse and dependence have become a major health
problem imposing a great burden on the society [13-15].
In recent years, a dramatic rise in methamphetamine use
has occurred in many countries [16]. There is evidence
for significantly increased prevalence of methampheta-
mine abuse in Iran in past years [17].
In the last decade, many medications have been used for
treatment of methamphetamine dependence including
modafinil, antidepressants, ondansetron, risperidone, aripi-
prazole, baclofen, topiramate, N-acetyl cysteine, naltrexone,
and gabapentin, but none demonstrated consistent efficacy
[2,10,13,18-25]. Some studies suggested sustained-releaseThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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pharmacotherapy for methamphetamine dependence
[26-30]. Given that methylphenidate antagonizes the ef-
fects of methamphetamine in vitro, some researchers
have tried it as a potential candidate for treatment of
methamphetamine dependence [31,32]. The results of
some preliminary studies have demonstrated that a main-
tenance pharmacotherapy program of daily sustained-
release amphetamine could increase retention of patients
and decrease relapse rate of methamphetamine depend-
ence [33] although a study has findings to the contrary
[34]. Some studies questioned the notion of replacement
therapy for amphetamine dependence (a cochrane review)
[35]. The objective of this randomized, double-blind,
placebo-controlled study was to evaluate the efficacy of
sustained-released methylphenidate in treatment of meth-
amphetamine dependence.
Methods
Trial design and setting
This study was a double-blind, randomized, placebo-
controlled trial. The participants (consecutive patients
screened for the trial) were men and women with
methamphetamine dependence attending outpatient
clinics in Sanandaj and Tehran from June 2013 to
August 2014.
Participants
Inclusion criteria were diagnosis of methamphetamine de-
pendence based on DSM-IV-TR between 18 to 65 years of
age, and positive methamphetamine urine test at the be-
ginning of the study. Participants met none of the follow-
ing exclusion criteria: (1) any other mental disorder on
axis I except for depression, (2) any serious medical or
neurological problem (3), IQ <70, (4) abuse of other sub-
stances except for nicotine and methadone over the last
six months; (5) history of Attention Defecit-Hyperactivity
Disorder (ADHD) during childhood, (6) pregnancy and
breast feeding, (7) development of psychotic symptoms
requiring pharmacotherapy and (8) serious suicidal idea-
tions. The study protocol was approved by the Institu-
tional Review Board of Tehran University of Medical
Sciences (Grant No: 16507) and was performed in accord-
ance with the Declaration of Helsinki and its subsequent
revisions. Patients gave written informed consent before
entry into the study. Patients were informed they are free
to withdraw from the study at any time, without giving
a reason. The trial was registered at the Iranian registry
of clinical trials (www.irct.ir; registration number:
IRCT201202281556N38) prior to conducting the study.
Interventions
Fifty-six individuals who met DSM-IV-TR criteria for meth-
amphetamine dependence participated in this 10-week trial.The participants were randomly allocated into two groups.
Group 1 received 18 mg/day sustained-released methyl-
phenidate during the first week and 36 mg/day during the
second week and then received 54 mg/day sustained-
released methylphenidate for the remaining 8 weeks. Group
2 received placebo for 10 weeks. The medication was given
daily under staff supervision.Outcome
Our primary outcome was Methamphetamine craving.
Craving was evaluated by a visual analogue craving scale
every week that ranges from 0 (no cravings) to 100
(most intense cravings possible) [22]. Data was gathered
by a demographic questionnaire and severity of addiction
was assessed by Addiction Severity Index (ASI) at the be-
ginning of the study. Several studies have shown that ASI
had acceptable reliability and validity [36-38]. It has been
reported that the Persian version of this inventory has
good reliability and validity [38,39]. Urinary screening test
for methamphetamine was carried out each week Urine
samples were analyzed using radioimmunoassay (Phama-
tech, Inc, San Diego, CA) for qualitative tests of MA me-
tabolite. The Beck Depression Inventory II (BDI-II) rating
scale was used to monitor participant depressive symp-
toms at baseline and bi-weekly during the treatment
period [40]. Medication adherence was measured using
weekly tablet counts justified against participant reports of
medication taking to calculate the proportion of dispensed
medication doses that were taken.Sample size
Assuming a clinically significant difference of 4 on the
visual analogue craving scale score between MPH-SR
and placebo groups with a standard deviation (SD) of
4.5 (based on our pilot study), a power of 80%, and a
two-sided significance level of 5%, a minimal sample size
of 40 was estimated. Considering an attrition rate of
10%, a total sample size of 48 was planned.Randomization, allocation, concealment and blinding
Generation of randomization codes was conducted by
permuted randomization block using Excel software
(blocks of four, allocation ratio 1:1). Randomization was
performed by an independent party who was not in-
volved elsewhere in the trial. Concealment of allocation
was performed using sequentially numbered, sealed,
opaque, and stapled envelopes. Separate persons were
responsible for generation of randomization codes, treat-
ment allocation and interviewing. The patients, research
investigators, nurses and interviewers were all blinded to
the treatment allocation. MPH-SR and placebo were com-
pletely identical in their size, color, shape, texture and odor.
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Mean differences between the groups were reported as
mean (95% confidence intervals (95% CI). All analyses were
based on the intention-to-treat sample and were per-
formed using the last observation carried forward (LOCF)
procedure. To compare the score and the behavior of the
two treatment groups over the course of the trial, two-
factor repeated measure analysis of variance (ANOVA)
was used. Greenhouse Geisser’s correction was used when-
ever Mauchly’s test of sphericity was significant. Compari-
son of score change from baseline to each time point
between the two groups was done using the unpaired
t-test. A p value of <0.05 was considered significant.
Results
Basic characteristics
Eighty-seven patients were screened to participate in
this study and a total number of 56 patients were en-
tered into the study. Ten patients from the MPH-SR
group and 12 patients from the placebo group dropped
out before week 6 and 34 patients completed the trial
(Figure 1). Baseline psychiatric characteristics, demo-
graphic and drug use of both groups were compared
yielding no significance between the two groups (Table 1).Figure 1 Flow diagram of the study.Urine drug screen results
There was no significant difference between the two
groups in baseline methamephetamine positive urine
drug screen tests. Nevertheless, at week 10, the MPH-SR
group was less methamphetamine positive compare to
the placebo and the difference was significant (P = 0.03)
(Figure 2).
Methamphetamine craving
Baseline Methamphetamine craving scores were not sig-
nificantly different between the treatment groups [MD
(95% CI) = 0.57(-3.97 to 5.12), t(54) = 0.25, p = 0.39]. At
the study endpoint, the result of repeated measure ana-
lysis demonstrated a significant effect of time × treat-
ment interaction [F = 4.06, p = 0.046] (Figure 3). By the
end of the trial, MPH-SR group showed significantly less
craving scores compared to the placebo group [MD
(95% CI) = -10.28(0.88-19.18), t(54) = 2.19, p = 0.03]
(Figure 3).
Depressive symptoms
Assessment of the baseline Depressive symptoms scores did
not reveal a significant difference between the treatment
groups [MD (95% CI) = -0.10(-1.18-0.97), t(54) = -0.19,
Table 1 Baseline characteristics of the participants, drug use and psychiatric characteristics
Mean (SD) or N Mean (SD) or N P value
Methylphenidate slow release (N = 28) Placebo (N = 28)
Age (years) 35.6(10.8) 34.7(11.5) ns
Gender, n 8 7 ns
• Female 20 21
• Male
Marital status, n ns
• Single 18 19
• Married 6 5
• Divorced 4 4
Level of education, n ns
• Illiterate 2 1
• Primary school 16 17
• High school diploma 8 9
• University degree 2 1
Smoking, n 25 26 ns
Use of methadone 12 11 ns
Employed, n 5 7 ns
Years of methamphetamine use 13.3(8.5) 12.8(9.1) ns
Days of methamphetamine use (past month) 10.2(8.7) 10.4(8.8) ns
Route of methamphetamine use, n ns
• Smoking 23 22
• Nasal 3 2
• Injection 1 1
• Oral 1 3
Addiction severity index composite score ns
• Medical 0.25(0.31) 0.28(0.26)
• Employment 0.22(017) 0.24(0.19)
• Alcohol 0.15(0.10) 0.14(0.13)
• Drug 0.28(0.1) 0.29(0.12)
• Legal 0.08(0.17) 0.07(0.16)
• Family/Social 0.22(0.23) 0.19(0.20)
• Psychiatric 0.24(0.25) 0.22(0.23
N: number; SD: Standard Deviation; ns: non-significant.
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significantly greater improvement in the depressive
symptom scores compared to the placebo group [MD
(95% CI) = 2.03(0.31-3.75), t(54) = 2.37, p = 0.02]. The
effect of time × treatment interaction was also significant
for the depressive symptom scores [F = 4.32, p = 0.02]
(Figure 4).Adverse events
No major adverse events or mortality occurred during
the period of this trial. As summarized in Table 2, a totalof 10 adverse events were recorded with no significant
difference in their frequency between the two groups
(Table 2).
Discussion
This preliminary study evaluated efficacy and safety of
once-daily sustained-release methylphenidate using a
double-blind, placebo-controlled design. Currently, there are
no approved pharmacological treatments for methampheta-
mine dependence. This randomized placebo-controlled
trial showed that slow-release methylphenidate can
successfully be used in order to reduce drug craving.
2D Graph 6
Week
























Figure 2 Positive urine drug screens in the two groups (%). NS indicates non-significant and * = p < 0.05.
Figure 3 Repeated measure for comparison of the effects of
two treatments on methamphetamine craving score. Values
represent mean ± standard deviation of the mean. P-values demonstrate
the result of the independent T-test for comparison of scores between
two treatment groups at each time point. NS indicates non-significant;
and * = p < 0.05.
Figure 4 Repeated measure for comparison of the effects of
two treatments on Beck Depression Inventory Score. Values
represent mean ± standard deviation of the mean. P-values demonstrate
the result of the independent T-test for comparison of scores between
two treatment groups at each time point. NS indicates non-significant;
and * = p < 0.05.
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Table 2 Frequency of adverse events in the study groups
Averse events Methylphenidate
slow selease, n
Placebo n P value
Anxiety 3 3 ns
Decreased appetite 3 2 ns
Depression 3 5 ns
Muscle aches 5 7 ns
Nausea 3 3 ns
Headache 10 5 ns
Irritability 5 8 ns
Stomachache 3 2 ns
Insomnia 8 9 ns
Dizzy 5 6 ns
ns: non-significant.
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less positive urine tests and it seemed that methylphenid-
ate may decrease use of methamphetamine. The results
of this study showed that depression decreased signifi-
cantly more in the methylphenidate arm compared with
the placebo arm.
Our results were in accordance with some previous stud-
ies [32,41,42]. Tiihonen and his colleagues have compared
methylphenidate with aripiprazol for treatment of meth-
amphetamine dependence, however, their study ended pre-
maturely due to unexpected results of interim analysis and
all of their patients were intravenous drug abuser; yet their
results have been promising. Solhi et al. showed that both
methylphenidate and risperidone were useful for decreas-
ing drug craving in patients but the duration of this
study was relatively short (3 weeks) and perhaps be-
cause of this the study failed to show the superiority of
methylphenidate.
Methylphenidate blocks the methamphetamine-induced
dopamine release and this effect may also antagonize the
rewarding and reinforcing effects of methamphetamine
and its use in dependent patients [31]. In addition, me-
thylphenidate also increases dopamine levels and therefore
may also act as substitution treatment for methampheta-
mine use [34,43]. Methamphetamine also releases nor-
epinephrine and norepinephrine is thought to contribute
to the acute effects of amphetamine-type drugs for the
treatment of methamphetamine addiction [44]. Methyl-
phenidate blocks the norepinephrine transporter and
these drugs could also block methamphetamine-induced
norepinephrine release [45].
Our results were inconsistent with the Miles study [34].
Miles et al. failed to confirm the usefulness of methyl-
phenidate for amphetamine/methamphetamine depend-
ence, but the retention rate in their study was low. In
studies with long duration the Miles study was 22 weeks),
the low retention rate is a major problem and one cannotnecessarily conclude that all dropped out patients had
experienced relapse. On the other hand, some studies
show that amphetamine use began to decrease substan-
tially as a function of time after 10 weeks of methylphenid-
ate treatment reaching statistical significance at 18 weeks,
which indicates that it may take an even longer period of
time than 20 weeks to achieve full benefit from this treat-
ment [32]. In these studies the participants were IV drug
users which represented a more severe subtype of sub-
stance dependence. However, our participants used meth-
amphetamine by smoking (the most common method of
methamphetamine abuse in Iran) and perhaps because of
this we could show the efficacy of methylphenidate in a
shorter period of time. In the Konsteniusa study, sustained
release methylphenidate could not affect craving for am-
phetamine or retention in treatment [46]. This study was
carried out on abstinent persons, but in our study partici-
pants were active users. In terms of safety, the frequency of
adverse events was not significantly different between the
two study arms during this study. However, the present
trial design was not particularly qualified for assessing the
safety profile of MPH-SR, a point which merits further
attention. This study has some limitations. The sample size
was relatively small. Larger studies are required to replicate
our findings. The effectiveness of methylphenidate beyond
10 weeks of treatment remains unknown.
Conclusion
Sustained-release methylphenidate was safe and well-
tolerated among active methamphetamine users and
significantly reduced methamphetamine use, craving and
depressive symptoms. This randomized placebo-controlled
trial showed that sustained-release methylphenidate can
successfully be used for treatment of methamphetamine
dependence.
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